2021
Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
Gottlieb A, Merola J, Cirulli J, Williams C, Linowski G, Paris M, Litman H, Guo N, Emeanuru K, McLean R, Cronin A, Strober B. Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry. Dermatology And Therapy 2021, 11: 253-263. PMID: 33475970, PMCID: PMC7858993, DOI: 10.1007/s13555-020-00479-4.Peer-Reviewed Original ResearchCorrona Psoriasis RegistryPsoriasis RegistryMost patientsPsoriatic arthritisRegistry enrollmentApremilast patientsPhase 3 clinical studiesReal-world observational studyConcomitant systemic treatmentPrior biologic exposureCharacteristics of patientsTreatment of psoriasisQuality of lifeHigh rateIndex dateObservational registrySevere psoriasisSystemic medicationsAdult patientsBiologic therapyPatient characteristicsSystemic treatmentBiologic exposureModerate diseasePsoriasis patients
2017
Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry
Strober B, Karki C, Mason M, Guo N, Holmgren S, Greenberg J, Lebwohl M. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. Journal Of The American Academy Of Dermatology 2017, 78: 323-332. PMID: 29051036, DOI: 10.1016/j.jaad.2017.10.012.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Inflammatory Agents, Non-SteroidalBiological ProductsBody Surface AreaComorbidityCost of IllnessCross-Sectional StudiesFatigueFemaleHumansInterleukin-12Interleukin-17Interleukin-23MaleMiddle AgedPainPatient Reported Outcome MeasuresProspective StudiesPsoriasisQuality of LifeRegistriesSeverity of Illness IndexThalidomideTumor Necrosis Factor-alphaUnited StatesConceptsCorrona Psoriasis RegistryPsoriasis RegistryDisease durationComparative safetyBody surface area involvementTumor necrosis factor inhibitorsIL-12/23 inhibitorsInterleukin-17A inhibitorInvestigator's Global AssessmentNecrosis factor inhibitorsSurface area involvementLonger disease durationCross-sectional studyLong-term safetyEfficacy of treatmentPsoriatic arthritis diagnosisQuality of lifeEfficacy of foodMultiple comorbiditiesRegistry cohortSystemic medicationsSystemic therapyFactor inhibitorsArea involvementBiologic treatment
2015
Current and Future Oral Systemic Therapies for Psoriasis
Kelly J, Foley P, Strober B. Current and Future Oral Systemic Therapies for Psoriasis. Dermatologic Clinics 2015, 33: 91-109. PMID: 25412786, DOI: 10.1016/j.det.2014.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAcitretinAnti-Inflammatory Agents, Non-SteroidalAntimetabolitesCyclosporineFumaratesHumansHydroxyureaImmunosuppressive AgentsIsoxazolesKeratolytic AgentsLeflunomideMethotrexateMycophenolic AcidPiperidinesProtein Kinase InhibitorsPsoriasisPyrimidinesPyrrolesSulfasalazineThalidomideThioguanine